Treatment of patients with parenteral/infusion therapy infected with sars-cov-2 in primary health care
Session
Medicine and Nursing
Description
Introduction: The beginning of 2020 took public health around the world with a new type of virus called Sars Cov-2, which for practical purposes was named by the WHO Covid-19. The virus was first identified in Wuhan, China. On January 30, 2020, the World Health Organization declared a public health emergency, while on March 11, it declared a global pandemic.
Aim: The purpose of this paper is to obtain data on patients infected with Sars Cov-2 who are treated with parenteral therapy at Primary Health Care (PHC). All PHC staff are constantly at risk of infection with Sars Cov-2. At KHPC, patients are treated with infusions, antibiotics, and anticoagulants. To highlight the role of PHC in managing the Covid-19 pandemic.
Methodology: This cross-sectional study was carried out between August 2021 and September 2021 at the Family Medicine Canter in Lipjan. As a sample in this study: N=200 patients of both sexes were taken in this study. N=100 patients during the month of August and N=100 patients during the month of September.
The research was carried out using the protocol books of parenteral therapy in the treatment room only for patients diagnosed with Covid-19 infection and parenteral therapy prescribed by the doctor. In the months of August and September 2021.
Description of practice change implemented: The analysis was performed to reflect differences from treatment with parenteral therapy before the official protocol by health professionals.
This survey presents the main findings that have enabled or hindered the full treatment of patients diagnosed with Covid-19. Based on the findings, health professionals will be guided to improve relevant services.
Targeted population and stakeholders: All ages that have received treatment as well as the infected PHC personnel. Timeline: August - September 2021.
Highlights – Results: Ampoules were given in infusion during the month, of August-September 2021 Total ampoules applied: August-182-F Sep-154-F Aug.-87-M Sep.-121-M Both sexes Aug.-269, Both sexes- Sep.-275. Total amp. 544 from them Antibiotics (Lendacin, Rotacef,Ceftriaxone)-129, Corticosteroids: Prednisolone-86, Dexamethasone-82, Fraxiparine-24, Ketonal-67, Ranital-49, Vit-C-85,
Conclusions and Discussion: The implementation of the protocols was inapplicable because it was compiled in August by the Ministry of Health and there were no prior recommendations for the treatment of patients who should be treated with therapy and infusions, as well as the selection of therapy!
Discussions: Although the current experience is limited due to the duration and the lack of more analyses, the messages received from patients and professionals are encouraging after the use of therapy applied by primary care physicians.
Lessons learned: Protocols must be compiled in time as well as eventual changes by the competent organizations, also the role of nurses in the last filtering before the application of therapy is a very important link. Also in the evidence of this therapy.
Keywords:
Pandemic, Covid-19, Treatment, Treatment with parenteral therapy, infusions, Protective measures.
Proceedings Editor
Edmond Hajrizi
ISBN
978-9951-550-50-5
Location
UBT Kampus, Lipjan
Start Date
29-10-2022 12:00 AM
End Date
30-9-2022 12:00 AM
DOI
10.33107/ubt-ic.2022.184
Recommended Citation
Krasniqi, Agim N. and Bytyqi, Leonit Xh., "Treatment of patients with parenteral/infusion therapy infected with sars-cov-2 in primary health care" (2022). UBT International Conference. 186.
https://knowledgecenter.ubt-uni.net/conference/2022/all-events/186
Treatment of patients with parenteral/infusion therapy infected with sars-cov-2 in primary health care
UBT Kampus, Lipjan
Introduction: The beginning of 2020 took public health around the world with a new type of virus called Sars Cov-2, which for practical purposes was named by the WHO Covid-19. The virus was first identified in Wuhan, China. On January 30, 2020, the World Health Organization declared a public health emergency, while on March 11, it declared a global pandemic.
Aim: The purpose of this paper is to obtain data on patients infected with Sars Cov-2 who are treated with parenteral therapy at Primary Health Care (PHC). All PHC staff are constantly at risk of infection with Sars Cov-2. At KHPC, patients are treated with infusions, antibiotics, and anticoagulants. To highlight the role of PHC in managing the Covid-19 pandemic.
Methodology: This cross-sectional study was carried out between August 2021 and September 2021 at the Family Medicine Canter in Lipjan. As a sample in this study: N=200 patients of both sexes were taken in this study. N=100 patients during the month of August and N=100 patients during the month of September.
The research was carried out using the protocol books of parenteral therapy in the treatment room only for patients diagnosed with Covid-19 infection and parenteral therapy prescribed by the doctor. In the months of August and September 2021.
Description of practice change implemented: The analysis was performed to reflect differences from treatment with parenteral therapy before the official protocol by health professionals.
This survey presents the main findings that have enabled or hindered the full treatment of patients diagnosed with Covid-19. Based on the findings, health professionals will be guided to improve relevant services.
Targeted population and stakeholders: All ages that have received treatment as well as the infected PHC personnel. Timeline: August - September 2021.
Highlights – Results: Ampoules were given in infusion during the month, of August-September 2021 Total ampoules applied: August-182-F Sep-154-F Aug.-87-M Sep.-121-M Both sexes Aug.-269, Both sexes- Sep.-275. Total amp. 544 from them Antibiotics (Lendacin, Rotacef,Ceftriaxone)-129, Corticosteroids: Prednisolone-86, Dexamethasone-82, Fraxiparine-24, Ketonal-67, Ranital-49, Vit-C-85,
Conclusions and Discussion: The implementation of the protocols was inapplicable because it was compiled in August by the Ministry of Health and there were no prior recommendations for the treatment of patients who should be treated with therapy and infusions, as well as the selection of therapy!
Discussions: Although the current experience is limited due to the duration and the lack of more analyses, the messages received from patients and professionals are encouraging after the use of therapy applied by primary care physicians.
Lessons learned: Protocols must be compiled in time as well as eventual changes by the competent organizations, also the role of nurses in the last filtering before the application of therapy is a very important link. Also in the evidence of this therapy.